LY-01011 is under clinical development by Luye Pharma Group and currently in Phase III for Giant Cell Tumor Of Bone. According to GlobalData, Phase III drugs for Giant Cell Tumor Of Bone does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the LY-01011 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LY-01011 overview

Denosumab biosimilar (LY-01011) is under development for the treatment of multiple myeloma, bone metastasis, giant cell tumor of bone and humoral hypercalcemia of malignancy. It is formulated as injection and administered through subcutaneous route. The drug candidate acts by targeting the receptor activator of nuclear factor kappa B ligand (RANKL).

Luye Pharma Group overview

Luye Pharma Group (Luye Pharma), a subsidiary of Luye Life Sciences Group Ltd, is a drug development company. It discovers, manufactures and commercializes novel formulations, generic drugs and pharmaceutical products. The company offers its products in the form of tablets, formulations for injections, capsules, gels, anti-psychotic medicines and modified-release dosages in the therapeutic areas of oncology, cardiovascular, orthopedics, hepatology, gastroenterology, gynecology, diabetes and central nervous system (CNS). Luye Pharma operates its research and development and manufacturing facilities in the US and China and, among others. Luye Pharma is headquartered in Yantai, Shandong, China.

For a complete picture of LY-01011’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.